Shanghai-based drug developer Hua Medicine has received US$25 million series B financing led by Hong Kong and U.S.-based healthcare investment firm Ally Bridge Group, according to a company announcement. Arch Venture Partners, Venrock, WuXi PharmaTech, SAIL Capital Partners, Fidelity Biosciences, TF Capital, and Frontline BioVentures also participated in the round, according to Ally Bridge's website. […]

Visit ChinaMoneyNetwork.com for more daily finance news, including audio and video Internet podcasts covering important investment news and financial events in China. Follow us on Twitter @chinamoneypod subscribe to all episodes on iTunes.